MUC5AC and cholangiocarcinoma: We firstly demonstrated the different sensitivity of the two CCA subtypes to chemotherapeutics since Gemcitabine and the Gemcitabine-Cisplatin combination were more active against mixed-CCA while Cisplatin or Abraxane were more effective in inhibiting cell proliferation in mucin-CCA primary cultures.